You are viewing the site in preview mode

Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways

Fig. 2

Proliferation and survival of CD19-specific CAR-NK cells with IL-21 expression. A Proliferation multiplicity of CAR, CAR-15 and CAR-21 NK cells in culturing with IL-2 maintenance (n = 4 donors). B IL-15 and IL-21 levels by ELISA from supernatants from non-transduced (NT), CAR, CAR-15 or CAR-21 NK cells (n = 4 donors). C The percentage of viable NK cells in cultures without IL-2 maintenance (n = 4 donors). D The numbers of viable NK cells in cultures without IL-2 maintenance (n = 4 donors). E The percentage of Annexin V positive NK cells in cultures without IL-2 maintenance (n = 4 donors).

Back to article page